Multiple sclerosis: failure of treatment with verapamil in a pilot trial
- PMID: 3950668
- DOI: 10.1007/BF00313996
Multiple sclerosis: failure of treatment with verapamil in a pilot trial
Abstract
Verapamil hydrochloride, a lipophilic calcium channel blocking agent was used in the treatment of 11 patients with multiple sclerosis. The rationale of the therapy was to improve the conduction capacity of the damaged nerve fibres. The therapy did not prove effective in a pilot trial.
Similar articles
-
Verapamil-induced changes in central conduction in patients with multiple sclerosis.J Neurol Neurosurg Psychiatry. 1985 Nov;48(11):1140-6. doi: 10.1136/jnnp.48.11.1140. J Neurol Neurosurg Psychiatry. 1985. PMID: 3001232 Free PMC article.
-
Calcium channel blocking drugs in the management of drug dependence, withdrawal and craving. A clinical pilot study with nifedipine and verapamil.Aust Fam Physician. 1998 Jan;27 Suppl 1:S19-24. Aust Fam Physician. 1998. PMID: 9503731 Clinical Trial.
-
The effect of oral verapamil on the visual evoked potentials in multiple sclerosis patients.Acta Neurol Taiwan. 2008 Sep;17(3):162-6. Acta Neurol Taiwan. 2008. PMID: 18975521 Clinical Trial.
-
Calcium-channel blocking agents.Clin Pharm. 1982 Jan-Feb;1(1):17-33. Clin Pharm. 1982. PMID: 6764159 Review.
-
Update on calcium-channel blocking agents.Clin Pharm. 1983 Sep-Oct;2(5):403-16. Clin Pharm. 1983. PMID: 6354566 Review.
References
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical